Pfizer Inc. $PFE Shares Purchased by PARK CIRCLE Co

PARK CIRCLE Co raised its holdings in Pfizer Inc. (NYSE:PFE) by 47.0% during the third quarter, HoldingsChannel.com reports. The firm owned 122,705 shares of the biopharmaceutical company’s stock after buying an additional 39,205 shares during the period. Pfizer makes up about 2.6% of PARK CIRCLE Co’s portfolio, making the stock its 10th biggest holding. PARK CIRCLE Co’s holdings in Pfizer were worth $3,127,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the 3rd quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $30,000. Darwin Wealth Management LLC bought a new position in shares of Pfizer during the second quarter worth about $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the second quarter worth about $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.58 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market capitalization of $156.78 billion, a PE ratio of 20.28 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The business’s fifty day moving average price is $25.84 and its two-hundred day moving average price is $25.23.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The company’s quarterly revenue was down 1.2% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Analysts Set New Price Targets

Several analysts have issued reports on PFE shares. Morgan Stanley cut their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Zacks Research lowered Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.